NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

$89.09

-2.39 (-2.61%)

(As of 10/7/2022 11:32 AM ET)

Add

Compare

Today's Range: $87.97
▼
$91.16
50-Day Range: $82.16
▼
$96.94
52-Week Range: $70.73
▼
$97.76

Volume: 18,389 shs
Average Volume: 1.05 million shs
Market Capitalization: $16.52 billion

P/E Ratio: 342.67
Dividend Yield: N/A
Price Target: $113.43

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 24.0% Upside
$113.43 Price Target
Short Interest: Bearish
6.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.93
Upright™ Environmental Score
News Sentiment: 0.61
Based on 5 Articles This Week
Insider Trading: Selling Shares
$2.87 M Sold Last Quarter
Proj. Earnings Growth: 186.96%
From $0.92 to $2.64 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

339th out of 1,075 stocks

Pharmaceutical Preparations Industry

147th out of 537 stocks

3.4

Analyst's Opinion

Consensus Rating
BioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $113.43, BioMarin Pharmaceutical has a forecasted upside of 24.0% from its current price of $91.48.
Amount of Analyst Coverage
BioMarin Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
6.32% of the float of BioMarin Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.
Change versus previous month
Short interest in BioMarin Pharmaceutical has recently increased by 0.61%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BioMarin Pharmaceutical does not currently pay a dividend.
Dividend Growth
BioMarin Pharmaceutical does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.
Environmental Sustainability
The Environmental Impact score for BioMarin Pharmaceutical is -2.93.

3.1

News and Social Media Coverage

News Sentiment
BioMarin Pharmaceutical has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for BioMarin Pharmaceutical this week, compared to 5 articles on an average week.
Search Interest
18 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
17 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 143% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,873,126.00 in company stock.
Percentage Held by Insiders
Only 1.75% of the stock of BioMarin Pharmaceutical is held by insiders.
Percentage Held by Institutions
94.84% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for BioMarin Pharmaceutical are expected to grow by 186.96% in the coming year, from $0.92 to $2.64 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioMarin Pharmaceutical is 351.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 114.48.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioMarin Pharmaceutical is 351.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 78.50.
Price to Earnings Growth Ratio
BioMarin Pharmaceutical has a PEG Ratio of 1.96. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
BioMarin Pharmaceutical has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

October 6, 2022 | markets.businessinsider.com

BioMarin Reduces About 4% Of Global Workforce

October 6, 2022 | finance.yahoo.com

BioMarin Simplifies Organizational Structure to Increase Efficiency

October 4, 2022 | finance.yahoo.com

BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET

October 2, 2022 | seekingalpha.com

BioMarin Pharmaceutical: Leader In Rare Disease Innovation

September 30, 2022 | finance.yahoo.com

BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy

September 30, 2022 | americanbankingnews.com

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Increased to $104.00 by Analysts at Stifel Nicolaus

September 30, 2022 | americanbankingnews.com

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $104.00 at Stifel Nicolaus

September 29, 2022 | finance.yahoo.com

BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA

September 23, 2022 | nasdaq.com

BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA

September 14, 2022 | seekingalpha.com

Catalyst Pharmaceuticals Ramp May Be Over For Now

September 14, 2022 | nasdaq.com

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Weighed On By Its Debt Load?

September 12, 2022 | seekingalpha.com

BioMarin investigates leukemia case in late-stage trial for hemophilia drug

September 3, 2022 | finance.yahoo.com

Neurocrine Leads 5 Stocks To Watch In Sickly Market

September 2, 2022 | finance.yahoo.com

Why Is BioMarin (BMRN) Down 2.3% Since Last Earnings Report?

August 25, 2022 | benzinga.com

First Gene Therapy for Adults with Severe...

August 25, 2022 | finance.yahoo.com

BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU

August 24, 2022 | nasdaq.com

European Commission Grants BioMarin's Roctavian CMA For Treatment Of Hemophilia A In Adult Patients

August 24, 2022 | finance.yahoo.com

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

August 24, 2022 | benzinga.com

BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate

August 24, 2022 | apnews.com

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

August 20, 2022 | thestreet.com

BioMarin Faces a Key Test of Rare Disease Pipeline

August 5, 2022 | nasdaq.com

June 2024 Options Now Available For BioMarin Pharmaceutical (BMRN)

August 4, 2022 | finance.yahoo.com

BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings

August 4, 2022 | finance.yahoo.com

BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

August 4, 2022 | seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q2 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings: 8/03/2022
Today: 10/07/2022
Next Earnings (Confirmed): 10/26/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BMRN
CUSIP: 09061G10
CIK: 1048477
Web: www.bmrn.com
Phone: (415) 506-6700
Fax: 415-382-7889
Employees: 3,045
Year Founded: 1997

Price Target and Rating

Average Stock Price Forecast: $113.43
High Stock Price Forecast: $135.00
Low Stock Price Forecast: $74.00
Forecasted Upside/Downside: +27.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.26
Trailing P/E Ratio: 342.67
Forward P/E Ratio: 96.84
P/E Growth: 1.96
Net Income: $-64,080,000.00
Net Margins: 2.83%
Pretax Margin: 2.95%
Return on Equity: 1.78%
Return on Assets: 1.28%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 5.42
Quick Ratio: 3.69

Sales & Book Value

Annual Sales: $1.85 billion
Price / Sales: 8.95
Cash Flow: $0.86 per share
Price / Cash Flow: 103.56
Book Value: $23.26 per share
Price / Book: 3.83

Miscellaneous

Outstanding Shares: 185,470,000
Free Float: 182,228,000
Market Cap: $16.52 billion
Optionable: Optionable
Beta: 0.33

Social Links

Key Executives

Mr. Jean-Jacques Bienaime M.B.A. (Age 69)
MBA, Chairman & CEO
Comp: $3.67M

Mr. Brian R. Mueller (Age 48)
Exec. VP of Fin. & CFO
Comp: $1.13M

Dr. C. Greg Guyer Ph.D. (Age 60)
CTO and Exec. VP of Global Manufacturing & Technical Operations
Comp: $1.75M

Mr. Jeffrey Robert Ajer (Age 60)
Exec. VP & Chief Commercial Officer
Comp: $1.2M

Dr. Henry J. Fuchs M.D. (Age 64)
Ph.D., Pres of Worldwide R&D
Comp: $1.52M

Ms. Erin Burkhart
Group VP & Chief Accounting Officer

Traci McCarty
VP of Investor Relations

Mr. George Eric Davis (Age 51)
Exec. VP, Gen. Counsel & Sec.

Mr. Philip Lo Scalzo
Sr. VP & Chief Compliance Officer

Ms. Humaira Serajuddin
Sr. VP & Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.
What is BioMarin Pharmaceutical's stock price forecast for 2022?: 14 brokerages have issued 1 year price targets for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $74.00 to $135.00. On average, they expect the company's stock price to reach $113.43 in the next twelve months. This suggests a possible upside of 24.0% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.
How have BMRN shares performed in 2022?: BioMarin Pharmaceutical's stock was trading at $88.35 at the start of the year. Since then, BMRN stock has increased by 3.5% and is now trading at $91.48.
View the best growth stocks for 2022 here.
When is BioMarin Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BMRN earnings forecast.
How can I listen to BioMarin Pharmaceutical's earnings call?: BioMarin Pharmaceutical will be holding an earnings conference call on Wednesday, October 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 757-849-6722 with passcode "2361#".
How were BioMarin Pharmaceutical's earnings last quarter?: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.13. The biotechnology company had revenue of $533.80 million for the quarter, compared to analyst estimates of $514.18 million. BioMarin Pharmaceutical had a net margin of 2.83% and a trailing twelve-month return on equity of 1.78%. During the same quarter in the prior year, the firm posted $0.23 earnings per share.
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?: BioMarin Pharmaceutical issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.11 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?: 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.
What other stocks do shareholders of BioMarin Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).
What is BioMarin Pharmaceutical's stock symbol?: BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."
Who are BioMarin Pharmaceutical's major shareholders?: BioMarin Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include AdvisorNet Financial Inc (0.01%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends.
How do I buy shares of BioMarin Pharmaceutical?: Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioMarin Pharmaceutical's stock price today?: One share of BMRN stock can currently be purchased for approximately $91.48.
How much money does BioMarin Pharmaceutical make?: BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $16.97 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.26 on an earnings per share basis.
How many employees does BioMarin Pharmaceutical have?: The company employs 3,045 workers across the globe.
How can I contact BioMarin Pharmaceutical?: BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

BioMarin Pharmaceutical MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows